Another study (MONARCH 2 and 3, ClinicalTrials.gov ID: NCT02107703 and NCT02246621, respectively) dealt with a combination of abemaciclib with other active compounds (fulvestrant and non-steroidal aromatase inhibitors) in breast cancer. The gene discussed is CYP19A1; the disease is breast cancer.